ArticleDiabetes, obesity & metabolism2019
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
Article in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Effects of Traditional Chinese Exercises on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Sports medicine (Auckland, N.Z.) · 2024Pooled it
- The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2022Pooled it
- Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies.Cardiovascular diabetology · 2019Pooled it
- The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.Nature medicine · 2023Trial
- Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers.Journal of the American Heart Association · 2020Trial
- Effects of Xuezhitong in Patients with Hypertriglyceridemia: a Multicentre, Randomized, Double-Blind, Double Simulation, Positive Drug and Placebo Parallel Control Study.Cardiovascular drugs and therapy · 2020Trial
- Omega-3 and Omega-6 Fatty Acids and Cardiovascular Outcomes in Diabetes - A Review of Current Evidence.Current diabetes reports · 2026Review
- Targeting triglycerides for cardiovascular risk reduction.Internal and emergency medicine · 2026Review
- The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.Cardiovascular diabetology · 2026Review
- Prognostic value of the atherogenic index of plasma in patients with multivessel coronary disease undergoing CABG: a retrospective cohort study.Lipids in health and disease · 2026Article
- Combined Effect of Low-Density Lipoprotein Cholesterol and Homocysteine on Major Adverse Cardiovascular Events in Coronary Heart Disease: A Retrospective Cohort Study.Reviews in cardiovascular medicine · 2026Article
- Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemia.Heart (British Cardiac Society) · 2025Review
- Machine learning-driven prediction models and mechanistic insights into cardiovascular diseases: deciphering the environmental endocrine disruptors nexus.Journal of translational medicine · 2025Article
- Hydroxytyrosyl Eicosapentaenoate as a Potential Antioxidant for Omega-3 Fatty Acids: Improved Synthesis and Comparative Evaluation with Other Natural Antioxidants.Biomolecules · 2025Article
- Atherogenic Index of Plasma (AIP) as a Long-Term Prognostic Factor Following CABG: Unveiling Insights From a Large-Scale Tertiary Center Registry Analysis.Health science reports · 2025Article
- Triglyceride levels and its association with all-cause mortality and cardiovascular outcomes among patients with heart failure.Nature communications · 2025Article
- A retrospective multicentre study on the outcomes of the pharmacist-managed Diabetes Medication Therapy Adherence Clinic programme in primary health clinics across Johor, Malaysia.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2025Article
- Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease.US cardiology · 2025Review
- Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition).Journal of translational internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine whether high triglycerides (TG) in the presence of statin-controlled LDL-C influence the risk of cardiovascular disease (CVD) among patients with diabetes in real-world clinical practice. MATERIALS AND
methodsWe identified adults with diabetes from the Southern California and Pacific Northwest regions of Kaiser Permanente. We included patients undergoing statin therapy with LDL-C from 40-100 mg/dL who were not undergoing other lipid-lowering therapies and had a prior diagnosis of atherosclerotic CVD or at least one other CVD risk factor. We grouped patients into high TG (200-499 mg/dL; n = 5542) or normal TG (<150 mg/dL, n = 22 411) from January 2010 through December 2016 to compare incidence rates and rate ratios of first non-fatal myocardial infarction (MI), non-fatal stroke, unstable angina and coronary revascularization. We adjusted multivariable analyses for age, sex, race/ethnicity, smoking status, blood pressure, HbA1c, serum creatinine, presence of ischaemic heart disease and study site.
resultsAdjusted rate ratios for the four outcomes were all statistically significantly different. The incidence rate for non-fatal MI was 30% higher in the high TG group (rate ratio, 1.30; 95% CI, 1.08-1.58; P = 0.006). The rate was 23% higher for non-fatal stroke (1.23, 1.01-1.49, P = 0.037), 21% higher for coronary revascularization (rate ratio, 1.21; 95% CI, 1.02-1.43; P = 0.027) and was, non-significantly, 33% higher for unstable angina (rate ratio, 1.33; 95% CI, 0.87-2.03; P = 0.185).
conclusionsDespite statin-controlled LDL-C levels, CV events were greater among patients with diabetes and high TG levels. Because we controlled for cardiometabolic risk factors, it is likely that the difference in TG levels contributed to the excess risk observed in patients with high TGs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.